Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | QL-X-138 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | KU-55933 | GDSC1000 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | clofarabine | CTRPv2 | pan-cancer | AAC | 0.012 | 0.7 |
mRNA | FGIN-1-27 | CTRPv2 | pan-cancer | AAC | 0.03 | 0.7 |
mRNA | FTI-277 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | VX-702 | GDSC1000 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | KIN001-266 | GDSC1000 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | navitoclax:PLX-4032 (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | -0.012 | 0.7 |
mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |